SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference, which takes place from August 5^th through 8^th.

Details for presentations related to GB001, an oral DP2 antagonist for eosinophilic asthma and chronic rhinosinusitis (CRS), are as follows:

Session Type: Thematic Poster Session
Session Title: Asthma Clinical Trials (B31)
Abstract Number: 3019
Poster Code: P378
Poster Title: Pharmacokinetics, Pharmacodynamics, and Safety of GB001 in Healthy Non-Asian, Non-Japanese Asian and Japanese Subjects
Link: https://bit.ly/2P36tKx

Session Type: Thematic Poster Session
Session Title: Asthma Subphenotypes, Targets and Therapeutics (D69)
Abstract Number: 7417
Poster Number: P409
Poster Title: GB001 Is a Differentiated Potent Prostaglandin D2 Antagonist with Long Receptor Residence Time and Extended Pharmacodynamic Efficacy
Link: https://bit.ly/2X6YZdR

Session Type: Thematic Poster Session
Session Title: Asthma Epidemiology (D31)
Abstract Number: 6478
Poster Number: P368
Poster Title: An Assessment of Asthma Control in a Real-World Setting
Link: https://bit.ly/333BNBd

Details for a presentation related to GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH), are as follows:

Session Type: Poster Discussion Session
Session Title: Up-To-Date PAH Assessment and Management (B27)
Abstract Number: 2907
Poster Number: P903
Poster Title: Phase 1a Randomized Double-Blind Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Studies of Orally Inhaled GB002 in Healthy Adult Subjects
Link: https://bit.ly/3f7GqfT

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005335/en/